Bringing the very best science and medicine to our best equine friends
News

Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference

SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer, will participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference, being held on October 11, 2017 in New York City. The event will feature one-on-one meetings at which investors will have the opportunity to meet with management to discuss key therapeutic programs in development and upcoming milestones. About Kindred Biosciences Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of …

Continue Reading

Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof

SAN FRANCISCO, Sept. 11, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Stephen Sundlof will retire in January of 2018 and that, simultaneous with his retirement, Dr. Hangjun Zhanwill be promoted to the position of Chief Scientific Officer. Dr. Zhan has over 20 years of experience in the biotechnology sector and is a world-renowned expert in protein design, expression, production, biochemistry, and biophysics. He holds a B.Sc. degree from Zhejiang University, M.S. and Ph.D. degrees from the University of Washington, and completed a post-doctoral fellowship at Harvard Medical School. Dr. Zhan is also the …

Continue Reading

Kindred Biosciences to Present at Upcoming Investor Conferences

SAN FRANCISCO, Aug. 30, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting at three, upcoming investor conferences in September 2017: 6th Annual Gateway Conference (September 6-7, 2017) Location:  Four Seasons Hotel, San Francisco, CA Presentation Date and Time:  September 6, 2017; 10:30 AM PT (Location TBD) Company Attendee:  Richard Chin, MD, Founder and CEO Rodman & Renshaw 19th Annual Global Investment Conference (September 11-12, 2017) Location:  Lotte New York Palace, New York, NY Presentation Date & Time:  September 11, 2017, 1:45 PM ET (Louis Room) Webcast URL:  http://wsw.com/webcast/rrshq27/kin Presenter:  Denise Bevers, Founder and COO Ladenburg Thalmann 2017 Healthcare Conference (September 26, 2017) Location:  …

Continue Reading

Kindred Biosciences Announces Second Quarter 2017 Financial Results

SAN FRANCISCO, Aug. 7, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2017 and provided updates on its programs. “We continue to look forward to our two upcoming approvals and launches. The commercial preparations for the launches are proceeding well and the feedback from the top opinion leaders on both of our products has been very positive,” stated Richard Chin, M.D., President and CEO of KindredBio. “We are continuing to make excellent progress across our pipeline, and are pleased to announce the completion of …

Continue Reading

Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting

SAN FRANCISCO, Aug. 4, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be sponsoring twenty veterinary students to attend the 2017 American Association of Feline Practitioners(AAFP) meeting to be held in Denver, CO October 19-22, 2017. Applicants included students from accredited veterinary colleges in the U.S. This sponsorship gives feline-focused veterinary students, who otherwise might not have the opportunity to attend, a chance to deepen their understanding and exposure to feline practice and to interact with prominent thought-leaders. “We are proud to support the recipients of the veterinary student sponsorship …

Continue Reading

Kindred Biosciences to Announce Second Quarter 2017 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Monday, August 7, 2017 SAN FRANCISCO, Calif., July 24, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its second quarter 2017 financial results on August 7, 2017 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 56145078. The …

Continue Reading

KindredBio Announces Pricing of Public Offering

SAN FRANCISCO, July 12, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $7.50 per share, for a total offering amount of $22.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio. KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock. All of the shares are being offered by KindredBio. …

Continue Reading